clopidogrel bisulfate tablet, film coated
dr.reddy's laboratories limited - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 300 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are
apixaban denk 2.5 mg film-coated tablets
denk pharma gmbh & co. kg prinzregentenstrasse 79 81675 münchen , germany - apixaban - film-coated tablet - apixaban 2.5 mg - antithrombotic agents
apixaban denk 5 mg film-coated tablets
denk pharma gmbh & co. kg prinzregentenstrasse 79 81675 münchen , germany - apixaban - film-coated tablet - apixaban 5 mg - antithrombotic agents
apixaban combino pharm 2.5 mg film-coated tablets
combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 2.5 mg - antithrombotic agents
apixaban combino pharm 5 mg film-coated tablets
combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - apixaban - film-coated tablet - apixaban 5 mg - antithrombotic agents
apixaban medichem 2.5 mg film-coated tablets
combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - film-coated tablet - apixaban 2.5 mg - antithrombotic agents
apixaban medichem 5 mg film-coated tablets
combino pharma (malta) ltd. hf60, hal far industrial estate, bbg07, hal far, malta - film-coated tablet - apixaban 5 mg - antithrombotic agents
clopidogrel clonmel 75 milligram film coated tablet
clonmel healthcare ltd - clopidogrel besilate - film coated tablet - 75 milligram - platelet aggregation inhibitors excl. heparin
clopidogrel tablet, film coated
direct rx - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - 1.1 acute coronary syndrome (acs) - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets, usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets, usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablets, usp therapy in acs is unknown. 1.2 recent mi, recent stroke, or established peripheral arterial disease for patients with a history of recent my
clopidogrel bisulfate tablet, film coated
sciegen pharmaceuticals inc - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - • clopidogrel is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non–st-segment elevation acs (unstable angina [ua]/ non–st -elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel should be administered in conjunction with aspirin. • clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel is indicated to reduce the rate of mi and stroke. clopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel is contraindicated in patients with hypersensitivity (e.